Market Overview
Pneumococcal is an infectious disease affected by the streptococcus pneumoniae bacteria, which may cause different illnesses such as ear infections, meningitis, and others. Pneumococcal polysaccharide vaccines are advised mostly for adults who suffer from pneumococcal infection.
The global 23-valent pneumococcal polysaccharide vaccine market size was valued US$ YY billion in 2020 and is estimated to reach US$ YY billion by 2028, growing at a CAGR of YY % during the forecast period (2021-2028)
Download free sample: https://www.datamintelligence.com/download-sample/23-valent-pneumococcal-polysaccharide-vaccine-market
Market Dynamics
Growing number of pneumococcal diseases associated with chronic disease patients is expected to drive the market growth.
According to the American Lung Association, Pneumococcal pneumonia is a potentially serious disease that can cause a range of different illnesses, including sinusitis, otitis media, pneumonia, bacteremia, osteomyelitis, septic arthritis and meningitis. Sinusitis affects 1 out of every seven adults in the United States, with more than 30 million individuals diagnosed each year. Moreover, the immune system naturally weakens with age, so even if you're healthy and active, being 65 or older is a key risk factor for pneumococcal pneumonia leading to an increased risk of chronic conditions, including COPD, Asthma, and heart disease Disease and Diabetes. Therefore it has led to an increase in the demand for the 23-Valent pneumococcal polysaccharide vaccine, which is expected to drive the market in the forecast period.
Side effects of PNEUMOVAX 23 (Pneumococcal Vaccine Polyvalent) are expected to hamper the market growth.
According to Merck, PNEUMOVAX 23 is a vaccine that is given as a shot. It helps protect from infection by certain germs or bacteria, which are called pneumococcus. Moreover, Pneumovax 23 vaccine is important for preventing infection in individuals at risk, including those with heart disease, lung disease, liver disease, kidney disease, diabetes, alcoholism, cirrhosis, spleen problems, sickle cell anemia, HIV, certain cancers, adults over 65 years of age. But the vaccine may not protect everyone who gets it, and it will not protect against diseases caused by bacteria types that are not in the vaccine. Besides the benefits of the vaccine, there are few side effects, including pain, warmth, soreness, redness, swelling, and hardening at the injection site, headache, weakness and feeling tired, and muscle pain. Thus, from the above statements, the market is expected to get hampered in the forecast period.
COVID-19 Impact Analysis
The coronavirus disease 2019 (COVID-19) pandemic is associated with high morbidity and mortality. Evidence shows that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, is originally transmitted through respiratory droplets from symptomatic, asymptomatic, or pre-symptomatic individuals. Like other respiratory pathogens, such as influenza, where approximately 25% of older patients get secondary bacterial infections, both superinfections and co-infections with SARS-CoV-2 have been reported. However, there is limited data on the frequency of co-infection and superinfections by viral, bacterial, or fungal infections and associated clinical outcomes among patients infected with SARS-CoV-2.
Moreover, the co-infection acts as the recovery of other respiratory pathogens in patients with SARS-CoV-2 infection at the time of a SARS-CoV-2 infection diagnosis and superinfection as the subsequent recovery of other respiratory pathogens during care for SARS-CoV-2 infection. Two previous reviews have examined the prevalence of bacterial and fungal co-infection or superinfection in SARS-CoV-2 infected patients. In addition, prior work suggests outcome differences in patients with co-infections vs. superinfections. For instance, Garcia-Vidal et al. showed that SARS-CoV-2 infected patients with superinfections had a longer hospital stay (LOS) and higher mortality. In contrast, those with co-infections had a higher frequency of admission to the ICU. Diagnostic testing and therapeutic decision-making may be altered by the presence of co-infection or superinfection with SARS-CoV-2 and other respiratory pathogens.
Additionally, the market faces challenges in manufacturing and delivering drugs due to an interrupted supply chain. Providing essential services due to lockdowns has led to reduced supply to the end-users. The pandemic is not likely to have long-term effects on end-users primary growth in the 23-valent pneumococcal polysaccharide vaccine market.
Segment Analysis
– By Age-Group
Children (2-10 years)*
Adults (10-64 years)
Geriatrics (65 years and above)
– By Dose Type
Single Dose Vial*
Pre-Filled Syringe
Geographical Analysis
North America region holds the largest market share in the global 23-valent pneumococcal polysaccharide vaccine market.
North America accounted for the largest revenue share in 2020. The growth is attributed to the high prevalence of bacterial pneumonia, well established vaccination program in the region, increasing prevalence of diseases, growing adoption of advanced vaccines, and large pool of key players, the largest supplier and consumption market of 23-valent pneumococcal polysaccharide vaccine, are the major factors that the market is expected to boost the forecast period. For instance, according to the American Lung Association, The most common type of bacterial pneumonia is called pneumococcal pneumonia. Pneumococcal pneumonia is caused by the Streptococcus pneumoniae germ that normally lives in the upper respiratory tract. It infects over 900,000 Americans every year. The greatest risk for bacterial pneumonia includes people recovering from surgery, people with respiratory disease or viral infection, and weakened immune systems.
Moreover, it causes more than a million hospitalizations and more than 50,000 deaths each year. Therefore, it has increased the demand for the 23-Valent pneumococcal polysaccharide vaccine, due to which the North American region is expected to hold the largest market share in the forecast period.
Competitive Landscape
The 23-valent pneumococcal polysaccharide vaccine market is vast with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc, Merck & Co., AstraZeneca, Baxter International Inc., Biogen Inc., Serum Institute of India, Eli Lilly and Company and Beijing Minhai Biotechnology. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the 23-valent pneumococcal polysaccharide vaccine market globally.
Merck & Co.:
Overview:
Merck & Co., Inc., outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891. The company develops and produces medicines, vaccines, biological therapies and animal health products. It has multiple blockbuster drugs or products, each with 2020 revenues, including cancer immunotherapy, anti-diabetic medication and vaccines against HPV and chickenpox. Moreover, the company is ranked 69th on the 2021 Fortune 500 and 92nd on the 2021 Forbes Global 2000, both based on 2020 revenues.
View full report: https://www.datamintelligence.com/research-report/23-valent-pneumococcal-polysaccharide-vaccine-market
Enquiry before buying: https://www.datamintelligence.com/enquiry/23-valent-pneumococcal-polysaccharide-vaccine-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866
Website: www.datamintelligence.com
A latest research report by IMARC group the titled is that “Pneumococcal Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026”, the global pneumococcal vaccine market grew at a CAGR of around 5% during 2015 & 2020.
Pneumococcal infections are caused by Streptococcus pneumoniae or pneumococcus bacteria, which can cause severe lung infection (pneumonia), blood infection (bacteremia), and infection in the lining of the brain and spinal cord (meningitis).
Children in the age group of 2-5 years and geriatric individuals are the most at-risk population for pneumococcal infections.
The pneumococcal vaccine market share stimulates the immune system and prevents the spread of infection, thereby eliminating the need for hospitalization and reducing the fatality rate.The rising parental concerns towards the high prevalence of pneumococcal infection in infants are propelling the demand for pneumococcal vaccines.
Furthermore, the growing geriatric population who are more prone to chronic respiratory diseases is also augmenting the market growth.
Additionally, the increasing consumption of cigarettes, snugs, cigars, hookah, etc., has further led to the rising incidences of severe lung diseases, thereby driving the global market.
Global Vaccine Conjugates Market OverviewConjugate vaccines are developed through a covalent bond between a weak antigen and a strong antigen.
The global vaccine conjugates market is anticipated to register a 14.5% CAGR over the forecast period of 2018-2027.
For instance, in July 2018, a Chinese vaccine manufacturer was found guilty of fabricating its manufacturing records and faced legal consequences.
On the basis of disease indication, the vaccine conjugates market is segmented into influenza, DTP, pneumococcal, and meningococcal.
Detailed Regional AnalysisThe global vaccine conjugates market is segmented into the regions of the Americas, Europe, Asia Pacific, and the Middle East and Africa.
Asia Pacific is anticipated to grow at a steady rate for vaccine conjugates during the forecast period.
The Pneumococcal Conjugate Vaccine Market 2021 research report gives emerging industry data, global segments and regional outlook.
The report generated using various analysis tools like porter’s five forces model, market attractiveness and value chain.
The report gives comprehensive review of the global market helping to club revenue generation and profitable business to transform client’s success.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the pneumococcal conjugate vaccine market include Glaxosmithkline plc, LG Chem Ltd., Merck & Co., Inc., Panacea Biotec Limited, Pfizer Inc., Pnuvax Incorporated, Serum Institute of India Pvt.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Pneumococcal Conjugate Vaccine Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/pneumococcal-conjugate-vaccine-market/download-sampleMarket DynamicsPneumococcal disease, one of the leading vaccine-preventable disorders, and one of the major causes of young children’s mortality rate worldwide is the key trend driving this market’s growth.
The demand for this vaccine is on the rise since it effectively prevents antibiotic-resistant pneumococcal infections caused by vaccine serotypes and the spread of the bacteria in the community.
